Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Jan;68(1):1-20.
doi: 10.1016/j.jinf.2013.08.019. Epub 2013 Sep 4.

Therapy of chronic hepatitis C virus infection in the era of direct-acting and host-targeting antiviral agents

Vincenza Conteduca  1 , Domenico Sansonno, Sabino Russi, Fabio Pavone, Franco Dammacco
Affiliations
Review

Therapy of chronic hepatitis C virus infection in the era of direct-acting and host-targeting antiviral agents

Vincenza Conteduca et al. J Infect. 2014 Jan.

Abstract

Objectives: Chronic hepatitis C virus (HCV) infection represents a leading worldwide medical and social problem. The expanding knowledge of HCV lifecycle has led to the development of novel antiviral agents that: a) specifically target a viral function (direct-acting antivirals), or b) specifically inhibit viral replication. The present review describes the novel anti-HCV drugs that have been better studied at the time of this writing and the current two types of treatment, namely interferon-based and interferon-free regimens. In addition, predictive factors, virological responses, side-effects, and resistance mechanisms of the novel agents are summarized.

Conclusions: The introduction of novel antiviral agents is remarkably changing the therapeutic combinations aimed at improving virological responses both for easy-to-cure and difficult-to-treat patients. Since additional, effective drugs are under advanced development, it seems reasonable to expect that further therapeutic and prognostic improvements will be achieved in the near future.

Keywords: BOC; CHC; CV; Chronic hepatitis C; DAA; DVR; Direct-acting antivirals; EVR; HCV; HTAs; Host-targeting antivirals; IFN-α; IL28B; ISGs; Interferon; NIs; NNIs; PI; Protease inhibitors; RBV; RGR; RVR; Ribavirin; SNP; SVR; SoC; TPV; boceprevir; chronic hepatitis C; cryoglobulinemic vasculitis; delayed virological response; direct-acting antiviral; eRVR; early virological response; extended rapid virological response; genotype; genotypes; gt; gts; hepatitis C virus; host-targeting antivirals; interferon-alpha; interferon-stimulated genes; interleukin 28B; non-nucleoside inhibitors; nucleoside analog inhibitors; pIFN; pegylated interferon; protease inhibitor; rapid virological response; response-guided regimens; ribavirin; single nucleotide polymorphism; standard of care; sustained virological response; telaprevir.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

Publication types

MeSH terms

LinkOut - more resources